Board of Directors
Andrew J M Richards, Ph.D., CBE (Chairman)
Andrew Richards is an established biotechnology entrepreneur and investor with extensive experience from the UK biotechnology sector in research, drug development, commercial deals and scale-up of companies. He is the Chairman of Congenica Ltd, Abcodia Ltd, Ieso Digital Health Ltd and Closed Loop Medicine Ltd as well as being a director of Owlstone Medical Ltd, Cancer Research Technology Ltd (the commercial board of Cancer Research UK) and The Scale-Up Institute.
Sarah Howell, Ph.D., Chief Executive Officer
Sarah Howell was appointed Chief Executive Officer of Arecor in 2015, having joined in 2011 as Chief Operating Officer and Executive Director. During her time at Arecor she has led the transformation of the business into a successful clinical stage biotechnology company. Sarah has a background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas.
Susan Lowther, Chief Financial Officer and Company Secretary
Susan Lowther was appointed Chief Financial Officer and Company Secretary at Arecor in 2019. She brings significant financial leadership experience across a broad range of public and private life science companies. Susan joined Arecor from IXICO plc, an imaging contract research organisation where she defined the financing strategy and raised growth capital taking the company on a path to profitability.
Sam Fazeli, Ph.D., Non-Executive Director
Sam Fazeli has served as a member of the Arecor Board of Directors since September 2017 and brings over twenty-two years of experience of conducting equity research as a pharmaceutical analyst, working at firms including Nomura International and HSBC. Currently, he is Director of EMEA Research and Senior Pharmaceutical Analyst at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals.
Jeremy Morgan, Non-Executive Director
Jeremy completed a Senior Executive Programme in General Management from London Business School and holds a BSc (Hons) in Applied Biology from Coventry University.
Alan E Smith, Ph.D., FRS, CBE, Non-Executive Director
Alan Smith is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation, Cambridge MA, where he had overall responsibility for the company’s science. Prior to its acquisition by Genzyme in 1989, Alan was the Vice President and Scientific Director of Integrated Genetics, a start-up biotechnology company. From 1980-84 he was head of the biochemistry division at the National Institute of Medical Research, Mill Hill, London. Presently, Alan sits on the Scientific Advisory Boards of Pharnext, a genomics company in Paris, France and he is on the Board of Directors of Candel Therapeutics (formerly Advantagene), an immune-oncology company in Needham MA.
Christine Soden, Non-Executive Director
Christine is a non-executive director of Elementis plc, the Cell and Gene Therapy Catapult, Fertility Focus Limited and Futurenova Limited and has previously served as chair of the audit committee at e-therapeutics plc, an AIM listed technology-based drug discovery platform from 2017 to February 2020 and at Provalis plc, a quoted healthcare business from 2000 to 2005. Christine is a Chartered Accountant and holds a degree in Mathematics from the University of Durham.